secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001437749-25-017185
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients
-------------------------------------------------------------------------------

- Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.
- Long-term OLE trial of brilaroxazine completed: 446 participants, 156 completed 12 months, 301 completed 6 months.
- Full OLE data (safety, efficacy, biomarkers) expected Q2 2025; registrational Phase 3 RECOVER-2 initiation expected mid-2025 subject to financing.
- NDA submission for brilaroxazine in schizophrenia targeted for Q4 2026; IND for psoriasis liposomal-gel formulation expected later in 2025.
- Company to present late-breaking poster on RECOVER 12-month OLE data at ASCP meeting on May 28, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/0001437749-25-017185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925017185/rvph20250507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-017185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer